Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
LFW Photonics Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cytokinetics
(NQ:
CYTK
)
59.69
+1.19 (+2.03%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Cytokinetics
< Previous
1
2
3
4
5
6
7
Next >
18 Analysts Have This to Say About Cytokinetics
May 05, 2023
Via
Benzinga
Cytokinetics: Q1 Earnings Insights
May 04, 2023
Via
Benzinga
Analyst Ratings for Cytokinetics
April 18, 2023
Via
Benzinga
Analyst Expectations for Cytokinetics's Future
March 31, 2023
Via
Benzinga
Cytokinetics Plans To Discontinue Late-Stage ALS Trial Due To Futility
March 31, 2023
Cytokinetics Incorporated (NASDAQ: CYTK) announced that the Data Monitoring Committee (DMC) for COURAGE-ALS recently convened to conduct the second planned interim analysis of this Phase 3 clinical...
Via
Benzinga
Analyst Ratings for Cytokinetics
March 06, 2023
Via
Benzinga
Cytokinetics Posts Aficamten Data In Patients With Thickened Heart Muscle
March 06, 2023
Via
Benzinga
FDA Rejects Cytokinetics' Heart Failure Treatment Candidate
March 01, 2023
Via
Benzinga
Earnings Scheduled For March 1, 2023
March 01, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.
Via
Benzinga
Cytokinetics's Earnings: A Preview
February 28, 2023
Via
Benzinga
Analyst Ratings for Cytokinetics
February 17, 2023
Via
Benzinga
Analyst Ratings for Cytokinetics
December 20, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 17, 2023
February 17, 2023
Via
Benzinga
A Patent Cliff Is Coming For Bristol — Can Billions In New Products Fill The Gap?
February 17, 2023
The company's biggest moneymakers are soon to lose patent protection.
Via
Investor's Business Daily
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
January 31, 2023
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...
Via
Benzinga
Expert Ratings for Cytokinetics
December 20, 2022
Via
Benzinga
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
December 27, 2022
Biopharma stocks were not immune to the broader market downturn seen for much of 2022.
Via
Benzinga
Tesla To $175? Here Are 10 Other Price Target Changes For Friday
December 23, 2022
Oppenheimer cut CarMax, Inc. (NYSE: KMX) price target from $100 to $75. . Oppenheimer analyst Brian Nagel maintained an Outperform rating on the stock. CarMax shares fell 1.3% to $56.47 in pre-market...
Via
Benzinga
What 7 Analyst Ratings Have To Say About Cytokinetics
December 20, 2022
Via
Benzinga
Cytokinetics AdComm Outcome Might Be Blessing In Disguise, This Analyst Said
December 14, 2022
Via
Benzinga
FDA Adcomm Gives Thumbs Down To Cytokinetics' Heart Failure Candidate
December 14, 2022
Via
Benzinga
Where Cytokinetics Stands With Analysts
October 11, 2022
Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2022
December 20, 2022
Via
Benzinga
REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday
December 14, 2022
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session
December 14, 2022
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.
Via
Benzinga
Why Cytokinetics Is Soaring After A 'Bruising' FDA Meeting For Its Heart Drug
December 14, 2022
The FDA's experts voted 3-8 against the Cytokinetics heart-failure drug.
Via
Investor's Business Daily
Top Stories Today: Jack Dorsey Not Exactly Impressed With Elon Musk's Twitter; Binance Sees $3B Outflow In 7 Days..
December 14, 2022
Benzinga
Via
Benzinga
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
December 02, 2022
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.
Via
Benzinga
Cytokinetics CEO: Why It's OK Not Being An Overnight Success
October 25, 2022
The company hopes to come out next year with at least one heart-failure drug.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
October 11, 2022
Upgrades
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.